Partial down-regulation of microglial CX3CR1 expression, and/or inhibition CX3CR1-fractalkine interactions should be explored as a potential therapeutic target to delay disease progression and improve cognition in AD. The gene discussed is CX3CR1; the disease is Alzheimer disease.